Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
NCT ID: NCT00960245
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
34 participants
INTERVENTIONAL
1994-07-31
1994-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Demonstrate the Relative Bioavailability of Atenolol Tablets
NCT00913965
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
NCT00145236
Nebivolol in Patients With Systolic Stage 2 Hypertension
NCT01057251
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans
NCT00145210
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
NCT00200460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
2
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Terry L. Wolff, D.O.
Role: PRINCIPAL_INVESTIGATOR
MeritCare Broadway Health Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRACS P94-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.